

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person AKKARAJU SRINIVAS <small>(Last) (First) (Middle)</small>		2. Date of Event Requiring Statement (Month/Day/Year) 06/08/2017		3. Issuer Name and Ticker or Trading Symbol Syros Pharmaceuticals, Inc. [SYRS]	
C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, SUITE 300 <small>(Street)</small>				4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	
CAMBRIDGE, MA 02139 <small>(City) (State) (Zip)</small>				5. If Amendment, Date Original Filed(Month/Day/Year) 06/12/2017	
				6. Individual or Joint/Group Filing(Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	740,740	I (U)	By Samsara BioCapital, L.P.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
AKKARAJU SRINIVAS C/O SYROS PHARMACEUTICALS, INC. 620 MEMORIAL DRIVE, SUITE 300 CAMBRIDGE, MA 02139	X			

Signatures

/s/ Srinivas Akkaraju	12/22/2017
<small>**Signature of Reporting Person</small>	<small>Date</small>

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These shares are owned directly by Samsara BioCapital, L.P. (the "LP"). The general partner of the LP is Samsara BioCapital GP, LLC (the "LLC"). The managers of the LLC are Srinivas Akkaraju and Michael Dybbes. These individuals may be deemed to have shared voting and investment and may be deemed to beneficially own certain shares held by the LP. Dr. Akkaraju disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such he is the beneficial owner of such securities.

Remarks:

This amendment is being filed solely to correct the number of shares of Common Stock reported in Table I that are held by the LP. In the original Form 3 and subsequently filed reports, the number of shares owned by the LP was inadvertently reported as 740,740.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.